Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label phase III study of KN057 injection for prophylaxis in hemophilia A and B without inhibitors
CTR20234255Phase 3Active
- Sponsor
- Alphamab Oncology
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Armocibart in hemophilia A, hemophilia B (HB), sponsored by Alphamab Oncology. Started Apr 2024; status: active.
02
Drugs
Armocibart
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20234255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234255.